Low-Dose Colchicine for ASCVD: Your Questions Answered

Michelle L. O'Donoghue, MD, MPH; Paul M. Ridker, MD, MPH

August 08, 2023

This transcript has been edited for clarity.

Michelle L. O'Donoghue, MD, MPH: Hi. This is Dr Michelle O'Donoghue, reporting for Medscape. Joining me today is Dr Paul Ridker. He's the Eugene Braunwald Professor of Medicine at Harvard Medical School. He's also the director of the cardiovascular prevention program at Brigham and Women's Hospital.

He's going to be joining me today to discuss a very important and emerging topic, which is the use of low-dose colchicine. I think there's much interest in the use of this drug, which now has a US Food and Drug Administration (FDA) indication, which we'll talk about further, and it's also been written into both European and American guidelines that have been recently released.

Many people are talking about where this fits into our current armamentarium, and I think there probably is no better person to discuss this than Paul Ridker, who's been at the forefront of research into anti-inflammatory therapeutics. Thank you for joining me, Paul.

Paul M. Ridker, MD, MPH: Michelle, it's a pleasure to be with you on Medscape today.

Lifestyle Lipid-Lowering Paramount

O'Donoghue: As we think about the concept behind the use of colchicine, we've obviously done a large amount of research into lipid-lowering drugs, but where does colchicine now fit in?

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.